A shortage of diabetes drug Ozempic that is used off-label for weight loss is expected in Canada, manufacturer Novo Nordisk and Health Canada said on Friday.
“We are experiencing a temporary supply disruption with the Ozempic 1 mg (injection) pen due to the combination of overall global supply constraints coupled with increased demand,” said Novo Nordisk spokesperson Kate Hanna in an emailed statement.
